Cyclometalated Iminophosphorane Gold(III) and Platinum(II) Complexes. A Highly Permeable Cationic Platinum(II) Compound with Promising Anticancer Properties
Frik, Malgorzata ; Fernández-Gallardo, Jacob ; Gonzalo, Óscar (Universidad de Zaragoza) ; Mangas-Sanjuan, Víctor ; González-Alvarez, Marta ; Serrano del Valle, Alfonso (Universidad de Zaragoza) ; Hu, Chunhua ; González-Alvarez, Isabel ; Bermejo, Marival ; Marzo, Isabel (Universidad de Zaragoza) ; Contel, María
Resumen: New organometallic gold(III) and platinum(II) complexes containing iminophosphorane ligands are described. Most of them are more cytotoxic to a number of human cancer cell lines than cisplatin. Cationic Pt(II) derivatives 4 and 5, which differ only in the anion, Hg2Cl62– or PF6– respectively, display almost identical IC50 values in the sub-micromolar range (25–335-fold more active than cisplatin on these cell lines). The gold compounds induced mainly caspase-independent cell death, as previously reported for related cycloaurated compounds containing IM ligands. Cycloplatinated compounds 3, 4, and 5 can also activate alternative caspase-independent mechanisms of death. However, at short incubation times cell death seems to be mainly caspase dependent, suggesting that the main mechanism of cell death for these compounds is apoptosis. Mercury-free compound 5 does not interact with plasmid (pBR322) DNA or with calf thymus DNA. Permeability studies of 5 by two different assays, in vitro Caco-2 monolayers and a rat perfusion model, have revealed a high permeability profile for this compound (comparable to that of metoprolol or caffeine) and an estimated oral fraction absorbed of 100%, which potentially makes it a good candidate for oral administration.
Idioma: Inglés
DOI: 10.1021/acs.jmedchem.5b00427
Año: 2015
Publicado en: Journal of medicinal chemistry 58, 15 (2015), 5825-5841
ISSN: 0022-2623
Factor impacto JCR: 5.589 (2015)
Categ. JCR: CHEMISTRY, MEDICINAL rank: 3 / 59 = 0.051 (2015) - Q1 - T1
Factor impacto SCIMAGO: 2.446 - Molecular Medicine (Q1) - Drug Discovery (Q1)
Financiación: info:eu-repo/grantAgreement/ES/MEC/FPU-AP2010-2372
Financiación: info:eu-repo/grantAgreement/ES/MINECO/SAF2010-1490
Tipo y forma: Article (Published version)
Área (Departamento): Área Biología Celular (Dpto. Bioq.Biolog.Mol. Celular)
You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes.
Exportado de SIDERAL (2021-01-21-11:20:47)
Visitas y descargas
Idioma: Inglés
DOI: 10.1021/acs.jmedchem.5b00427
Año: 2015
Publicado en: Journal of medicinal chemistry 58, 15 (2015), 5825-5841
ISSN: 0022-2623
Factor impacto JCR: 5.589 (2015)
Categ. JCR: CHEMISTRY, MEDICINAL rank: 3 / 59 = 0.051 (2015) - Q1 - T1
Factor impacto SCIMAGO: 2.446 - Molecular Medicine (Q1) - Drug Discovery (Q1)
Financiación: info:eu-repo/grantAgreement/ES/MEC/FPU-AP2010-2372
Financiación: info:eu-repo/grantAgreement/ES/MINECO/SAF2010-1490
Tipo y forma: Article (Published version)
Área (Departamento): Área Biología Celular (Dpto. Bioq.Biolog.Mol. Celular)
You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. Exportado de SIDERAL (2021-01-21-11:20:47)
Permalink:
Visitas y descargas
Este artículo se encuentra en las siguientes colecciones:
Articles > Artículos por área > biologia_celular
Record created 2020-01-03, last modified 2021-01-21